| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Quince Therapeutics, Inc. | Director | Common Stock | 8K | $7.52K | $0.94 | Aug 8, 2023 | Direct |
| Quince Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 27K | Jun 5, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| QNCX | Quince Therapeutics, Inc. | Aug 8, 2023 | 1 | $9.84K | 4 | Aug 9, 2023 | Director |
| QNCX | Quince Therapeutics, Inc. | May 24, 2023 | 1 | $0 | 4 | May 26, 2023 | Director |
| QNCX | Cortexyme, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
| QNCX | Cortexyme, Inc. | Oct 8, 2021 | 3 | -$71.9K | 4 | Oct 12, 2021 | Director |
| QNCX | Cortexyme, Inc. | Aug 16, 2021 | 7 | -$471K | 4 | Aug 18, 2021 | Director |
| QNCX | Cortexyme, Inc. | Jun 28, 2021 | 3 | -$30.3K | 4 | Jun 29, 2021 | Director |
| QNCX | Cortexyme, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |